CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma

Cluster of differentiation (CD)-73 plays pivotal roles in the regulation of immune reactions via the production of extracellular adenosine, and the overexpression of CD73 is associated with worse outcomes in several types of cancers. Here, we identified 167 esophageal squamous cell carcinoma (ESCC)...

Full description

Bibliographic Details
Main Authors: Yen-Hao Chen, Hung-I Lu, Chien-Ming Lo, Shau-Hsuan Li
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/13/16/3982
_version_ 1797524444981231616
author Yen-Hao Chen
Hung-I Lu
Chien-Ming Lo
Shau-Hsuan Li
author_facet Yen-Hao Chen
Hung-I Lu
Chien-Ming Lo
Shau-Hsuan Li
author_sort Yen-Hao Chen
collection DOAJ
description Cluster of differentiation (CD)-73 plays pivotal roles in the regulation of immune reactions via the production of extracellular adenosine, and the overexpression of CD73 is associated with worse outcomes in several types of cancers. Here, we identified 167 esophageal squamous cell carcinoma (ESCC) patients who underwent esophagectomy, including 64 and 103 patients with high and low expression levels of CD73, respectively. Univariate and multivariate analyses showed high expression of CD73 was an independent prognostic factor for worse disease-free survival and overall survival. In addition, we selected another cohort consisting of 38 ESCC patients receiving nivolumab or pembrolizumab and found that treatment response and survival benefit to immunotherapy were strongly correlated with the expression levels of CD73/programmed death ligand 1. Moreover, the transwell assay revealed knockdown of CD73 in two ESCC cell lines, TE1 and KYSE30, exhibited significantly reduced abilities of cell invasion and migration. CD73 silencing also showed that the protein expression levels of CD73, vimentin, and snail were downregulated, while those of E-cadherin were upregulated in Western blotting. The findings of our study indicate CD73 may be an independent prognostic factor for ESCC patients who underwent esophagectomy. Furthermore, it may be associated with the patient responses to immunotherapy.
first_indexed 2024-03-10T08:57:30Z
format Article
id doaj.art-681b756ed0b842339b0a7f6b45ec1f21
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-10T08:57:30Z
publishDate 2021-08-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-681b756ed0b842339b0a7f6b45ec1f212023-11-22T07:02:22ZengMDPI AGCancers2072-66942021-08-011316398210.3390/cancers13163982CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell CarcinomaYen-Hao Chen0Hung-I Lu1Chien-Ming Lo2Shau-Hsuan Li3Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDepartment of Thoracic & Cardiovascular Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDepartment of Thoracic & Cardiovascular Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDepartment of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanCluster of differentiation (CD)-73 plays pivotal roles in the regulation of immune reactions via the production of extracellular adenosine, and the overexpression of CD73 is associated with worse outcomes in several types of cancers. Here, we identified 167 esophageal squamous cell carcinoma (ESCC) patients who underwent esophagectomy, including 64 and 103 patients with high and low expression levels of CD73, respectively. Univariate and multivariate analyses showed high expression of CD73 was an independent prognostic factor for worse disease-free survival and overall survival. In addition, we selected another cohort consisting of 38 ESCC patients receiving nivolumab or pembrolizumab and found that treatment response and survival benefit to immunotherapy were strongly correlated with the expression levels of CD73/programmed death ligand 1. Moreover, the transwell assay revealed knockdown of CD73 in two ESCC cell lines, TE1 and KYSE30, exhibited significantly reduced abilities of cell invasion and migration. CD73 silencing also showed that the protein expression levels of CD73, vimentin, and snail were downregulated, while those of E-cadherin were upregulated in Western blotting. The findings of our study indicate CD73 may be an independent prognostic factor for ESCC patients who underwent esophagectomy. Furthermore, it may be associated with the patient responses to immunotherapy.https://www.mdpi.com/2072-6694/13/16/3982esophageal cancerCD73squamous cell carcinomaepithelial–mesenchymal transitionesophagectomy
spellingShingle Yen-Hao Chen
Hung-I Lu
Chien-Ming Lo
Shau-Hsuan Li
CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma
Cancers
esophageal cancer
CD73
squamous cell carcinoma
epithelial–mesenchymal transition
esophagectomy
title CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma
title_full CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma
title_fullStr CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma
title_full_unstemmed CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma
title_short CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma
title_sort cd73 promotes tumor progression in patients with esophageal squamous cell carcinoma
topic esophageal cancer
CD73
squamous cell carcinoma
epithelial–mesenchymal transition
esophagectomy
url https://www.mdpi.com/2072-6694/13/16/3982
work_keys_str_mv AT yenhaochen cd73promotestumorprogressioninpatientswithesophagealsquamouscellcarcinoma
AT hungilu cd73promotestumorprogressioninpatientswithesophagealsquamouscellcarcinoma
AT chienminglo cd73promotestumorprogressioninpatientswithesophagealsquamouscellcarcinoma
AT shauhsuanli cd73promotestumorprogressioninpatientswithesophagealsquamouscellcarcinoma